Key result
Myeloid Trem2 deletion sharply attenuates atherosclerosis progression by limiting macrophage proliferation and promoting cell death.
Demonstrates Trem2's role in atherosclerotic plaque growth via macrophage regulation, suggesting a potential therapeutic target.
Atherosclerotic plaque formation is driven by the continued expansion of cholesterol loaded ‘foamy’ macrophages within the arterial intima. Foamy macrophages are primarily derived from newly recruited monocytes, but factors regulating monocyte specification toward foamy macrophage differentiation and prolonged survival in plaque remain poorly understood. We used trajectory analysis of integrated single cell RNA-seq data, along with a genome-wide CRISPR screening approach to identify Triggering Receptor Expressed on Myeloid Cells 2 (Trem2) as a candidate regulator for foamy macrophage specification. Loss of Trem2 led to a reduced ability of foamy macrophages to take up additional oxidized low density lipoprotein (LDL) cholesterol in vitro. Competitive chimera experiments showed that Trem2-deficient macrophages were less competent to form foamy macrophages when competed against Trem2-sufficient macrophages in vivo. In addition, myeloid specific conditional deletion of Trem2 resulted in a dramatic attenuation of plaque progression, even when targeted in established atherosclerotic lesions. This was independent of changes in circulating inflammatory cytokines, monocyte recruitment, or serum cholesterol levels, but due to a reduction in plaque macrophage proliferation and enhanced cell death. Mechanistically, we link Trem2-deficient macrophages with an inability for cells to sense cholesterol loading and failure to upregulate efflux molecules. Accumulation of cholesterol in the endoplasmic reticulum enhanced activation of the ER-stress response that increased susceptibility for cholesterol-toxicity and cell death in foamy Trem2-deficient macrophages. Overall, this study identifies Trem2 as a regulator of foamy macrophage differentiation, atherosclerotic plaque growth, and as a putative therapeutic target for future intervention studies.
No takes yet. Share an insight, caveat, or question.
Patterson et al. (2022) studied Atherosclerosis. Trem2 deficiency vs. Trem2-sufficient macrophages was evaluated on Atherosclerotic plaque progression and foamy macrophage lipid uptake. Myeloid-specific conditional deletion of Trem2 dramatically attenuated atherosclerotic plaque progression by reducing macrophage proliferation and enhancing cell death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: